Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Simple noninvasive systems predict long-term outcomes in NAFLD

The latest issue of Gastroenterology investigates simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

News image

Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications, and have higher mortality than other patients with NAFLD.

Dr Paul Angulo and colleagues from Kentucky, USA determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death.

The research team performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011.

Patients were assigned to mild-, intermediate-, or high-risk groups based on cut-off values for 2 of the following; NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score.

Outcomes included liver-related complications and death or liver transplantation.

14% of patients developed liver-related events
Gastroenterology

The researchers used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios.

During a median follow-up period of 105 months, 14% of patients developed liver-related events, and 13% died or underwent liver transplantation.

The adjusted hazard ratios for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 8, and 34, respectively.

Based on NAFLD fibrosis score, the adjusted hazard ratios for liver-related events in the intermediate-risk and high-risk groups were 8.8, and 21 based on the aspartate aminotransferase/platelet ratio index; and 6.2 and 6.6 based on the BARD score.

The adjusted hazard ratios for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2, and 9.8, respectively, based on the NAFLD fibrosis scores.

Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation.

Dr Angulo's team concludes, "Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death."

"NAFLD fibrosis score appears to be the best indicator of patients at risk."

"The results of this study require external validation."

Gastroenterology 2013: 145(4): 782-789
08 October 2013

Go to top of page Email this page Email this page to a colleague

 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 23 June 2016 
Touch screens in the IBD outpatient clinic
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Breath as a marker for IBS
 10 June 2016 
Rectal cancer surgery checklist
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care
 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Predicting relapse in IBD
 01 June 2016 
Treatment of Hep C/HIV after liver transplant
 31 May 2016 
Markers as a reflection of inflammatory burden in ulcerative colitis
 31 May 2016 
Predicting Crohn's diseases before diagnosis
 31 May 2016 
Biomarker predicts post ERCP pancreatitis
 30 May 2016 
Challenges for direct-acting antivirals in Hep C
 30 May 2016 
Endoscopic indices for disease activity in ulcerative colitis
 30 May 2016 
Colonoscopy reimbursement reduction in practice

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us